SAGE

Sage Therapeutics, Inc. (SAGE) | Rumor.io

Sage Therapeutics

SAGE

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)69%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about SAGE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jul 31

Supernus Pharmaceuticals has completed its acquisition of Sage Therapeutics, offering $8.50 per share plus contingent value rights (CVRs) worth up to $3.50 per share, tied to future milestones of their drug Zurzuvae.
Sage Therapeutics shareholders will receive a maximum of $3.50 per share in CVRs, contingent on U.S. net sales of Zurzuvae reaching specific milestones by 2026, 2027, 2028, or 2030.
Sage Therapeutics has been acquired by Supernus Pharmaceuticals, with the acquisition expected to close, and the company's stock price has been suspended on Webull.

Generated by AI

Sentiment

Of the messages about SAGE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	86.88% -0.54
Bearish	—	—	—	13.12% +0.54

Bullish· Jun 16

$SAGE is being acquired by Supernus Pharmaceuticals in a deal worth up to $795 million, with a potential target price of $12 per share.
The acquisition premium offers a short-term arbitrage opportunity, with expected upside of 38%-52%.
The company's FDA-approved oral treatment for postpartum depression, Zurzuvae, has significant sales potential, with potential milestones worth up to $1.00 per share in CVR.

Bearish· Aug 8

The author believes that biotech funds, including those holding $SAGE, are being shorted, and the $XBI index is stuck in a trading range.
$SAGE's recent price bounce is attributed to analyst downgrades, which the author views as a sign of the company's fundamental weakness.
The author expects $SAGE to drop further, potentially to around $16 per share, and warns against getting caught in a short covering rally.

Generated by AI

Topics

Of the messages about SAGE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	1.49%
Announcements	—	—	—	95.69%
Controversies	—	—	—	2.23%
Earnings	—	—	—	0.15%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0.45%

Analysts· Aug 8

Analysts have downgraded Sage Therapeutics' ($SAGE) price target, with some cutting it by as much as $19.
Analysts' confidence in Sage Therapeutics ($SAGE) is mixed, with a buy consensus of 77% and some analysts downgrading the stock.
Analysts have expressed varying opinions on Sage Therapeutics ($SAGE), with some downgrading the stock due to a CRL in MDD and others maintaining a hold rating.

Announcements· Jun 16

Supernus Pharmaceuticals is acquiring Sage Therapeutics for $8.50 per share in cash, plus a contingent value right (CVR) that can potentially pay out up to $3.50 per share.
The total deal value is approximately $795 million, with the CVR tied to the sales of Sage's postpartum depression drug Zurzuvae.
The transaction is expected to close in the third quarter of 2025, subject to customary closing conditions, including receipt of required regulatory approvals.

Technical Analysis· Dec 5

$SAGE is looking for a reversal entry with a max stop at $58, and the price action is an overreaction for a company with a thicker pipeline.
The price of $SAGE is expected to recover in a couple of weeks, with some analysts suggesting a potential bounce play around $62-$65.
The long-term support for $SAGE is around $28.32, and some traders are considering buying at this level for a potential long-term opportunity.

Generated by AI

Community

Of the messages about SAGE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	24.75%
Newcomers	—	—	100%	75.25%

Regulars· Jun 16

Supernus will acquire Sage Therapeutics for $8.50 per share in cash, plus a non-traditable contingent value right (CVR) worth up to $3.50 per share, totaling up to $795M.
The acquisition is seen as a potential "steal" due to the mispriced optionality of the deal, with some regulars suggesting that Supernus may have gotten a good deal.
The acquisition will strengthen Supernus' neuropsychiatry product portfolio, which includes Sage's FDA-approved oral medicine for adults with postpartum depression, ZURZUVAE (zuranolone).

Newcomers· Jun 16

Supernus Pharmaceuticals is acquiring Sage Therapeutics in a deal worth up to $795 million, with a potential $3.50 share in contingent value rights.
The acquisition is expected to strengthen Supernus's neuropsychiatry product portfolio, particularly with Sage's FDA-approved oral treatment for postpartum depression.
Traders should monitor clinical trial or collaboration updates from Sage Therapeutics, as strong gains and recovery from yearly lows suggest potential for future growth.

Generated by AI

News

Cantor Fitzgerald initiates Dyne Therapeutics stock with overweight rating

2mo agoInvesting.com

Also Discussed

Investors talking about SAGE also mention

#	Name	Attention
1	MRNS - Marinus Pharmaceuticals, Inc.	——
2	BPMC - Blueprint Medicines Corporation	——
3	Neurocrine Biosciences, Inc.NBIX	0%new
4	Biogen IncBIIB	0%-0.01
5	Axsome Therapeutics IncAXSM	0.01%0
6	BLUE - bluebird bio, Inc.	——
7	Xencor Inc.XNCR	0%new
8	Agios Pharmaceuticals, Inc.AGIO	0%0
9	ITCI - Intra-Cellular Therapies, Inc.	——
10	SGEN - Seagen Inc.	——